Bazedoxifene and bazedoxifene combined with conjugated estrogens for the management of postmenopausal osteoporosis

Bibliography

• KLIBANSKI A, ADAMS-CAMPBELL L, BASSFORD T et al.: Osteoporosis prevention, diagnosis, and therapy. JAMA (2001) 285(6):785-795.
   PubMed Web of Science ®Google Scholar
• DENNISON E, COOPER C: Epidemiology of osteoporotic fractures. Horm. Res. (2000) 54(Suppl.):63.
   Google Scholar
• CENTER JR, NGUYEN TV, SCHNEIDER D, SAMBROOK PN, EISMAN JA: Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet (1999) 353(9156):878-882.
   PubMed Web of Science ®Google Scholar
• COOPER C: The crippling consequences of fractures and their impact on quality of life. Am. J. Med. (1997) 103(2A):S12-S19.
   PubMed Web of Science ®Google Scholar
• BURGE R, DAWSON-HUGHES B, SOLOMON DH, WONG JB, KING A, TOSTESON A: Incidence and economic burden of osteoporosis-related fractures in the United States, 2005 – 2025. J. Bone Miner. Res. (2007) 22(3):465-475.
   PubMed Web of Science ®Google Scholar
• RIGGS BL, PARFITT AM: Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. (2005) 20(2):177-184.
   PubMed Web of Science ®Google Scholar
• ANDERSON GL, LIMACHER M, ASSAF AR et al.: Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 291(14):1701-1712.
   PubMed Web of Science ®Google Scholar
• WRITING GROUP FOR THE WOMEN'S HEALTH INITIATIVE INVESTIGATORS: Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA (2002) 288:321-333.
   PubMed Web of Science ®Google Scholar
• CAULEY JA, ROBBINS J, CHEN Z et al.: Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 290(13):1729-1738.
   PubMed Web of Science ®Google Scholar
• SYED FA, MODDER UI, FRASER DG et al.: Skeletal effects of estrogen are mediated by opposing actions of classical and nonclassical estrogen receptor pathways. J. Bone Miner. Res. (2005) 20(11):1992-2001.
   PubMed Web of Science ®Google Scholar
• CAMPBELL S, WHITEHEAD M: Oestrogen therapy and the menopausal syndrome. Clin. Obstet. Gynaecol. (1977) 4(1):31-47.
   PubMed Web of Science ®Google Scholar
• POWLES TJ: Tamoxifen for prevention of breast cancer: report of the national surgical adjuvant breast and bowel project P-1 study. J. Natl. Cancer Inst. (1999) 91(8):730.
   PubMedGoogle Scholar
• BARAKAT RR: The effect of tamoxifen on the endometrium. Oncology (Williston Park) (1995) 9(2):129-134.
   PubMedGoogle Scholar
• ETTINGER B, BLACK DM, MITLAK BH et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene – results from a 3-year randomized clinical trial. JAMA (1999) 282(7):637-645.
   PubMed Web of Science ®Google Scholar
• VOGEL VG, COSTANTINO JP, WICKERHAM DL et al.: Effects of tamoxifen versus raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA (2006) 295(23):2727-2741.
   PubMed Web of Science ®Google Scholar
• KOMM BS, LYTTLE CR: Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann. NY Acad. Sci. (2001) 949:317-326.
   PubMed Web of Science ®Google Scholar
• GRUBER C, GRUBER D: Bazedoxifene (Wyeth). Curr. Opin. Investig. Drugs (2004) 5(10):1086-1093.
   PubMedGoogle Scholar
• MILLER CP: SERMs: evolutionary chemistry, revolutionary biology. Curr. Pharm. Des. (2002) 8(23):2089-2111.
   PubMed Web of Science ®Google Scholar
• PATAT A, MCKEAND W, BAIRD-BELLAIRE S, ERMER J, LECOZ F: Absolute/relative bioavailabilty of bazedoxifene acetate in healthy postmenopausal women. Clin. Pharmacol. Ther. (2003) 73(2):P43.
   Web of Science ®Google Scholar
• CHANDRASEKARAN A, ERMER J, MCKEAND W et al.: Bazedoxifene acetate metabolic disposition in healthy, postmenopausal women. Clin. Pharmacol. Ther. (2003) 73(2):P47.
   Web of Science ®Google Scholar
• ERMER J, MCKEAND W, SULLIVAN P, PARKER V, ORCZYK G: Bazedoxifene acetate dose proportionality in healthy, postmenopausal women. Clin. Pharmacol. Ther. (2007) 73(2):P46.
   Google Scholar
• ERMER JC, KOTAKE A, MCKEAND WE, MILLER M, ORCZYK GP: Clinical pharmacology of a novel tissue selective estrogen (WAY-140424) in postmenopausal women following administration for 30 days. J. Bone Miner. Res. (2000) 15(Suppl. 1):S436.
   Web of Science ®Google Scholar
• BAIRD SJ, MCKEAND WE, ERMER JC, PATAT AA, GARCIA, QUETGLAS E: Lack of clinically relevant pharmacokinetic interaction between bazedoxifene and ibuprofen. Clin. Pharmacol. Ther. (2002) 71(2):P94.
   Web of Science ®Google Scholar
• KOMM BS, KHARODE YP, BODINE PV, HARRIS HA, MILLER CP, LYTTLE CR: Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology (2005) 146(9):3999-4008.
   PubMed Web of Science ®Google Scholar
• STUMP AL, KELLEY KW, WENSEL TM: Bazedoxifene: a third-generation selective estrogen receptor modulator for treatment of postmenopausal osteoporosis. Ann. Pharmacother. (2007) 41(5):833-839.
   PubMed Web of Science ®Google Scholar
• KOMM BS, BODINE PVN, MINCK DR: Effects of bazedoxifene acetate on bone loss: a 12-month study in ovariectomized rats. J. Bone Miner. Res. (2007) 22(Suppl. 1):S58.
   Web of Science ®Google Scholar
• SMITH SY, MINCK D, JOLETTE J, CHOUINARD L, TURNER CH, KOMM B: Bazedoxifene prevents ovariectomy-induced bone loss in the cynomolgus monkeys. J. Bone Miner. Res. (2005) 20(Suppl. 1):S174.
   Web of Science ®Google Scholar
• MERCHENTHALER I, FUNKHOUSER JM, CARVER JM, LUNDEEN SG, GHOSH K, WINNEKER RC: The effect of estrogens and antiestrogens in a rat model for hot flush. Maturitas (1998) 30(3):307-316.
   PubMed Web of Science ®Google Scholar
• RONKIN S, NORTHINGTON R, BARACAT E et al.: Endometrial effects of bazedoxifene acetate, a novel selective estrogen receptor modulator, in postmenopausal women. Obstet. Gynecol. (2005) 105(6):1397-1404.
   PubMed Web of Science ®Google Scholar
• BOUDES P, RONKIN S, KORNER S, BARACAT E, CONSTANTINE G: Effects of bazedoxifene (TSE-424), a novel tissue selective estrogen receptor modulator (SERM), on the incidence of breast pain. Osteoporos. Int. (2003) 14(Suppl. 7):S14.
   Web of Science ®Google Scholar
• RONKIN S, CLARKE L, BOUDES P, CONSTANTINE G: TSE-424, a novel tissue selective estrogen, reduces biochemical indicies of bone metabolism in a dose related fashion. J. Bone Miner. Res. (2001) 16(Suppl. 1):S413.
   Google Scholar
• MILLER PD, CHRISTIANSEN C, HOECK HC et al.: Efficacy of bazedoxifene for prevention of postmenopausal osteoporosis: results of a 2-year, Phase III, placebo- and active-controlled study. J. Bone Miner. Res. (2007) 22(Suppl. 1):S59.
   Google Scholar
• CHESNUT CH, CHRISTIANSEN C, HOECK HC et al.: Safety and tolerability of bazedoxifene for the prevention of postmenopausal osteoporosis. J. Bone Miner. Res. (2007) 22(Suppl. 1):S460.
   Google Scholar
• SILVERMAN SL, CHRISTIANSEN C, GENANT HK et al.: Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopoausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J. Bone Miner. Res. (2007) 22(Suppl. 1):S58.
   Web of Science ®Google Scholar
• ADACHI JD, CHESNUT CH III, BROWN JP et al.: Safety and tolerability of bazedoxifene in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo- and active-controlled clinical trial. J. Bone Miner. Res. (2007) 22(Suppl. 1):S460.
   Google Scholar
• VAN DUREN D, RONKIN S, PICKAR J, CONSTANTINE G: Bazedoxifene combined with conjugated estrogens: a novel alternative to traditional hormone therapies. Fertil. Steril. (2006) 86(Suppl. 1):S88-S89 (Abstract O-206).
   Web of Science ®Google Scholar
• PICKAR J, ARCHER DF, CONSTANTINE G, RONKIN S, SPEROFF L: A double-blind, placebo-controlled, Phase III study of bazedoxifene/conjugated estrogens in postmenopausal women: effects on endometrium. Program and abstracts of the 89th Annual Meeting of the Endocrine Society, Toronto, Canada (2 – 5 June 2007) (Abstract P1-350).
   Google Scholar
• LINDSAY R, RONKIN S, CONSTANTINE G, OLIVIER S, PICKAR J: A double-blind, placebo-controlled, Phase III study of bazedoxifene/conjugated estrogens in postmenopausal women: effects on BMD. Program and abstracts of the 89th Annual Meeting of the Endocrine Society, Toronto, Canada (2 – 5 June 2007) (Abstract OR38-3).
   Google Scholar